Cardiology
Evolocumab Before PCI Lowers LDL, Not 1-Year Outcomes
In AMUNDSEN, evolocumab started before PCI rapidly lowered LDL cholesterol after acute myocardial infarction but did not improve clinical outcomes at 1 year.
Rayan Salih · 7 min read
The archive
All stories
484 stories, newest first — page 3 of 21.
Latest briefs
Oncology
Atezolizumab Approved for Stage III dMMR Colon Cancer
The FDA approved adjuvant atezolizumab plus chemotherapy for adults and patients aged 12 years or older with resected stage III mismatch-repair-deficient colon cancer.
Rayan Salih · 6 min read
Neurology
Rebisufligene Opens a Pathway for Sanfilippo Type A
FDA approval establishes the first treatment pathway for pediatric Sanfilippo syndrome type A. Exact eligibility and monitoring should be confirmed against the prescribing information.
Rayan Salih · 7 min read
Innovation & Devices
Bravo CF Recall Requires Removal From Esophageal Testing
The FDA’s Class I classification means gastroenterology and motility services should identify, quarantine and remove affected Bravo CF delivery devices while reviewing scheduled esophageal pH studies.
Rayan Salih · 6 min read
Clinical Briefs
Tucatinib Maintenance Approval Needs Source Verification
The supplied FDA index does not provide enough decision-specific information to verify a new tucatinib, trastuzumab and pertuzumab maintenance indication.
Rayan Salih · 6 min read
Oncology
FDA Approves Atezolizumab for Stage III dMMR Colon Cancer
The FDA approved adjuvant atezolizumab plus chemotherapy for adults and children aged 12 years and older with resected stage III mismatch-repair-deficient colon cancer.
Rayan Salih · 7 min read
Oncology
Cyclophosphamide Recall Prompts Inventory, Exposure Review
Three cyclophosphamide injection lots were recalled nationwide after steel particulate matter was found. Oncology teams need to trace inventory and review possible patient exposure.
Rayan Salih · 6 min read
Innovation & Devices
Bravo CF pH Device Recall Follows 184 Serious Injuries
The Class I recall covers Bravo CF delivery devices that may not attach or release the esophageal pH capsule as intended. Gastroenterology services should review inventory, prior procedures and testing alternatives.
Rayan Salih · 6 min read
Cardiology
Impella Introducer Correction Highlights Major Bleeding Risk
The FDA's Class I correction covers catheter introducer kits used with Impella heart pumps. Bleeding complaints, including reports associated with deaths, make rapid product identification and clinical vigilance essential.
Rayan Salih · 7 min read
Infectious Disease
FDA Class I Recall: Aspergillus Contamination in IV-Start and Convenience Kits
An FDA Class I recall covers IV-start and convenience kits containing skin-preparation products contaminated with Aspergillus penicillioides. Health systems need coordinated inventory tracing and exposure review.
Dr. Abu Bakar · 7 min read
Mental & Behavioral Health
Psilocybin May Ease Treatment-Resistant Depression
Randomized evidence suggests psilocybin-assisted therapy can reduce depressive symptoms through six weeks, but safety, durability and implementation questions limit its immediate US clinical role.
Dr. Abu Bakar · 6 min read
Clinical Briefs
FDA Alert: Recall of Glutathione, Myers’ Cocktail and Tri-Immune Boost Injections
A nationwide recall covers compounded glutathione, Myers’ cocktail and Tri-Immune Boost injections. Infusion practices should quarantine affected stock and review patient exposure.
Dr. Abu Bakar · 7 min read
Cardiology
SGLT2 Inhibitors vs GLP-1 Receptor Agonists: What Cardiovascular Evidence Shows
A randomized-trial review favors SGLT2 inhibitors for heart failure hospitalization, while mortality differences from GLP-1 receptor agonists remain less certain.
Dr. Abu Bakar · 6 min read
Clinical Briefs
FDA Issues Temporary Guidance on Neonatal Starter Parenteral Nutrition Compounding
Temporary FDA guidance creates a regulatory bridge for neonatal starter parenteral nutrition as the predominant market source prepares to exit. Hospital pharmacies still must meet the policy’s conditions and core quality obligations.
Dr. Abu Bakar · 7 min read
Clinical Briefs
Catheter Recall Expands Over Particulate Safety Risks
The FDA expanded a Class I recall covering specific lots of reprocessed electrophysiology and ultrasound catheters because particulates may remain on patient-contacting surfaces.
Dr. Abu Bakar · 6 min read
Clinical Briefs
Sodium Chloride Recall Raises Potassium Exposure Risk
One recalled lot labeled as 0.9% sodium chloride injection may expose patients to concentrated potassium chloride. Hospitals, pharmacies and infusion services should rapidly isolate affected inventory and trace possible use.
Rayan Salih · 6 min read
Innovation & Devices
Astral Ventilator Class I Recall Raises Backup Needs
Supercapacitor electrolyte leakage may damage circuit boards in affected ResMed Astral ventilators. Ventilator-dependent patients need a functional backup and a rehearsed response plan.
Rayan Salih · 6 min read
Health Policy
Class I Epidural Kit Recall Requires Inventory Controls
An FDA Class I recall covers single-shot epidural and epidural/pain kits containing sodium chloride injection ampules, requiring kit-level quarantine and case planning.
Rayan Salih · 6 min read
Neurology
Sanfilippo Gene Therapy Hinges on Preserved Function
The first gene therapy for pediatric Sanfilippo syndrome type A is intended for children whose neurodevelopmental function remains preserved, making early assessment and referral central to eligibility.
Rayan Salih · 7 min read
Clinical Briefs
Dexmedetomidine Recall Requires Lot and Exposure Checks
Par Health recalled two lots of dexmedetomidine injection over particulate matter. Hospitals should trace inventory, replace affected infusions and assess exposed patients.
Rayan Salih · 7 min read
Cardiology
SGLT2 Inhibitors, Finerenone and Semaglutide Differ
A meta-analysis of 10 randomized datasets and 37,923 participants found distinct cardiorenal outcome patterns across SGLT2 inhibitors, finerenone and semaglutide, arguing against treating them as interchangeable.
Rayan Salih · 7 min read
Endocrinology & Metabolism
FDA Approves First Treatment for MCT8 Deficiency
The FDA approved tiratricol as the first treatment for peripheral thyrotoxicosis in MCT8 deficiency, targeting cardiovascular and metabolic manifestations rather than the disorder’s established neurologic disability.
Dr. Abu Bakar · 6 min read
Health Policy
WHO Moves to Expand Access to Lifesaving Sickle Cell Treatment and Care for Children
WHO’s access initiative shifts the pediatric sickle cell agenda toward delivery. Health systems must connect early diagnosis with preventive care, treatment, referral and long-term follow-up through age 19.
Dr. Abu Bakar · 6 min read
Infectious Disease
Baxter Recalls One Lot of Cefazolin in Dextrose Injection After Cardboard Particles Found
Baxter recalled one lot of cefazolin in dextrose injection after cardboard particulate matter was found. Pharmacies and perioperative teams should isolate affected inventory while maintaining prophylaxis workflows.
Dr. Abu Bakar · 6 min read